| Diabetes Mellitus, Non-Insulin-Dependent
Jardiance vs Glyxambi
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Jardiance vs Glyxambi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsGlyxambi has a higher rate of injection site reactions vs Jardiance based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Glyxambi but not Jardiance, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Jardiance
Glyxambi
At A Glance
Oral
Once daily
SGLT2 inhibitor
Oral
Daily
SGLT2 inhibitor / DPP-4 inhibitor
Indications
- Heart failure
- Chronic Kidney Diseases
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
- Cardiovascular Diseases
Dosing
Heart failure, Chronic Kidney Diseases 10 mg orally once daily in the morning, taken with or without food.
Diabetes Mellitus, Non-Insulin-Dependent 10 mg orally once daily in the morning, taken with or without food; may increase to 25 mg once daily in patients tolerating 10 mg for additional glycemic control.
Diabetes Mellitus, Non-Insulin-Dependent, Cardiovascular Diseases 10 mg empagliflozin/5 mg linagliptin once daily in the morning, with or without food; may increase to 25 mg empagliflozin/5 mg linagliptin once daily for additional glycemic control; not recommended with eGFR less than 30 mL/min/1.73 m2; withhold at least 3 days prior to surgery or procedures associated with prolonged fasting.
Contraindications
- Hypersensitivity to empagliflozin or any excipient in JARDIANCE (reactions such as angioedema have occurred)
- Hypersensitivity to empagliflozin, linagliptin, or any excipient in GLYXAMBI (including anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity)
Adverse Reactions
Most common (>=2%) Urinary tract infection, female genital mycotic infections, upper respiratory tract infection, increased urination, dyslipidemia, arthralgia, male genital mycotic infections, nausea
Serious Diabetic ketoacidosis, volume depletion, urosepsis, pyelonephritis, necrotizing fasciitis of the perineum (Fournier's gangrene), hypoglycemia (with insulin or sulfonylurea), hypersensitivity reactions
Postmarketing Constipation, necrotizing fasciitis of the perineum, urosepsis, pyelonephritis, ketoacidosis, acute kidney injury, angioedema, skin reactions (rash, urticaria)
Most common (>=5%) Urinary tract infection, nasopharyngitis, upper respiratory tract infection
Serious Diabetic ketoacidosis, pancreatitis, volume depletion, urosepsis, pyelonephritis, necrotizing fasciitis of the perineum, genital mycotic infections, hypoglycemia with insulin or insulin secretagogues, lower limb amputation, hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid, heart failure
Postmarketing Acute pancreatitis including fatal pancreatitis, constipation, mouth ulceration, stomatitis, anaphylaxis, angioedema, exfoliative skin conditions, necrotizing fasciitis of the perineum, urosepsis, pyelonephritis, ketoacidosis, rhabdomyolysis, acute kidney injury, bullous pemphigoid, rash, urticaria
Pharmacology
Empagliflozin is an SGLT2 inhibitor that reduces renal reabsorption of filtered glucose, lowers the renal threshold for glucose, and increases urinary glucose excretion; it also reduces sodium reabsorption, which may increase tubuloglomerular feedback, reduce intraglomerular pressure, and lower cardiac pre- and afterload.
Empagliflozin is a SGLT2 inhibitor that reduces renal glucose reabsorption by inhibiting the predominant transporter responsible for filtered glucose reabsorption, thereby increasing urinary glucose excretion; linagliptin is a DPP-4 inhibitor that increases active incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and reducing glucagon levels.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Jardiance
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (9/12) · Qty limit (11/12)
Glyxambi
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (4/12) · Qty limit (11/12)
UnitedHealthcare
Jardiance
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Glyxambi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (4/8) · Qty limit (6/8)
Humana
Jardiance
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Glyxambi
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$10/momo
Jardiance Savings CardCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Glyxambi.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
JardianceView full Jardiance profile
GlyxambiView full Glyxambi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.